Sonoma Pharmaceuticals, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2024. Although the request metadata refers to 2023 Q4, this filing reports the full fiscal year and compares it with the year ended March 31, 2023.
Business context
Sonoma develops and manufactures stabilized hypochlorous acid (HOCl) products for human and animal health care and disinfectant markets. It sells directly and through partners in 55 countries; manufacturing is centered in Zapopan, Mexico. Human-care revenue grew, while the company continued cost-containment efforts and increased investment in product development and regulatory work.
Financial performance and liquidity
| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Revenue | $12.735 million | $13.272 million |
| Gross profit / margin | $4.745 million / 37% | $4.477 million / 34% |
| Operating loss | $4.701 million | $4.570 million |
| Net loss | $4.835 million | $5.151 million |
| Net loss per share | $0.53 | $1.52 |
| Cash used in operating activities | $2.398 million | $6.152 million |
| Cash and cash equivalents at year-end | $3.128 million | $3.820 million |
| Working capital at year-end | $8.829 million | $10.081 million |
- Revenue declined 4%. Product revenue rose to $12.313 million from $11.926 million: human-care revenue increased to $10.110 million from $9.426 million, while animal-care revenue fell to $2.203 million from $2.500 million. Service and royalty revenue decreased to $422,000 from $1.346 million.
- Operating expenses were $9.446 million, up from $9.047 million. Research and development rose sharply to $1.871 million from $207,000; selling, general and administrative expense declined to $7.575 million from $8.840 million.
- Short-term debt was $323,000 at March 31, 2024. The balance sheet also showed $4.710 million in withholding tax payable. The company disclosed substantial intercompany amounts owed by its Mexican subsidiary, with loans maturing in 2027.
- Financing activities provided $1.676 million, primarily from common-stock sales. The company reported $1.185 million of cash deposits above federally insured limits.
Changes, outlook and material risks
- Gross margin improved by three percentage points, which management attributed principally to product mix, labor redeployment to R&D and higher prior-year materials and transportation costs. The net loss narrowed, but operating loss increased as R&D spending rose.
- Regional revenue was mixed: Europe increased 18% to $4.781 million; U.S. revenue fell 11% to $3.058 million; Asia declined 6% to $2.298 million; and Latin America declined 28% to $1.726 million. The Latin America comparison included $750,000 of prior-year service revenue from a one-time machinery sale.
- Management expects revenue to fluctuate and losses to continue in the foreseeable future. It may need additional financing; availability and terms are uncertain. The auditor’s report and management’s disclosure state that substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Common shares outstanding increased from 4.93 million at March 31, 2023 to 15.61 million at March 31, 2024, principally reflecting equity financing. After year-end, the company sold 3.17 million additional shares for net proceeds of approximately $762,000; 18.77 million shares were outstanding as of June 17, 2024.
- A proposed FDA rule could require new 510(k) submissions and compliance with special controls for certain HOCl wound-care products if finalized. The filing also cites dependence on distributors and key customers, international and foreign-exchange exposure, product and regulatory risks, and potential dilution from future capital raises.
- The company identified material weaknesses in internal control over financial reporting, including spreadsheet controls, segregation of preparation and review, and revenue analysis. Remediation steps were underway but had not operated long enough to be considered effective. The auditor gave an unqualified opinion on the financial statements, included a going-concern section, and reported no critical audit matters; the auditor did not audit internal-control effectiveness.
- Nasdaq had granted an extension through September 16, 2024, for the company to regain compliance with the $1 minimum bid-price requirement. Failure to comply could put the listing at risk.
- Management disclosed an estimated $4.7 million of Mexican withholding taxes associated with intercompany interest and technical-assistance payments if repaid, alongside broader tax and intercompany-debt exposure. It is reviewing options with tax advisers. The filing provides no numeric revenue or earnings guidance.
Important facts for investors to verify
- Cash runway, financing needs and progress toward resolving the auditor’s going-concern concern.
- Whether revenue growth in human care and Europe is sustained, and the effect of customer concentration and distributor order timing.
- The status and potential cost of the proposed FDA rule and any resulting 510(k) requirements.
- Remediation and testing of internal controls, especially revenue recognition and financial-reporting review.
- Mexican intercompany debt, withholding-tax exposure, and the availability and recoverability of prepaid Mexican taxes.
- Nasdaq bid-price compliance and the dilutive impact of recent and potential future share issuance.